Status:
COMPLETED
Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients
Lead Sponsor:
Sir Charles Gairdner Hospital
Conditions:
Kidney Failure, Chronic
Anemia
Eligibility:
All Genders
Brief Summary
The purpose of this study is to audit the effects of changing all hemodialysis patients from intravenous to subcutaneous administration of ESA's, to ensure that a cost-saving is achieved and that this...
Detailed Description
Background Erythropoietin Stimulating Agents (ESAs) are widely used by chronic kidney disease patients who suffer with renal associated anemia. Until recently there have been only two ESAs currently ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- On haemodialysis at a Sir Charles Gairdner Hospital Unit
Exclusion
Key Trial Info
Start Date :
September 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2008
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00382044
Start Date
September 1 2006
End Date
April 1 2008
Last Update
May 23 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia, 6009